PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsEfavirenz
Sustiva, Stocrin(efavirenz)
Efavirenz, Efavirenz / / Tenofovir Disoproxil, Stocrin, Sustiva, Symfi (efavirenz) is a small molecule pharmaceutical. Efavirenz was first approved as Sustiva on 1998-09-17. It is used to treat acquired immunodeficiency syndrome and HIV infections in the USA. It has been approved in Europe to treat HIV infections. It is known to target cytochrome P450 3A4.
Download report
Favorite
BMS
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
urogenital diseasesD000091642
immune system diseasesD007154
Trade Name
FDA
EMA
Efavirenz (discontinued: Efavirenz, Sustiva)
Combinations
Efavirenz, emtricitabine, tenofovir disoproxil, Efavirenz, lamivudine tenofovir disoproxil, Symfi, Symfi lo (discontinued: Atripla, Efavirenz, lamivudine tenofovir disoproxil, Efavirenz; emtricitabine tenofovir disoproxil, Efavirenz; emtricitabine; tenofovir disoproxil)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Efavirenz
+
Lamivudine
+
Tenofovir disoproxil fumarate
Tradename
Company
Number
Date
Products
SYMFI LOMylanN-208255 RX2018-02-05
1 products, RLD, RS
SYMFIMylanN-022142 RX2018-03-22
1 products, RLD, RS
Show 2 discontinued
Efavirenz
Tradename
Company
Number
Date
Products
SUSTIVABristol Myers SquibbN-020972 DISCN1998-09-17
3 products, RLD
SUSTIVABristol Myers SquibbN-021360 DISCN2002-02-01
2 products, RLD
Hide discontinued
Efavirenz
+
Emtricitabine
+
Tenofovir disoproxil fumarate
Tradename
Company
Number
Date
Products
ATRIPLAGilead SciencesN-021937 DISCN2006-07-12
1 products, RLD
Hide discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
atriplaNew Drug Application2017-01-23
efavirenzANDA2024-06-28
efavirenz, emtricitabine and tenofovir disoproxil fumarateANDA2025-07-28
efavirenz, lamivudine and tenofovir disoproxil fumarateANDA2024-05-07
sustivaNew Drug Application2013-01-02
symfiNew Drug Application2019-10-15
symfi loNew Drug Application2019-10-15
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
hiv infectionsEFO_0000764D015658B20
hiv—D006678O98.7
acquired immunodeficiency syndromeEFO_0000765D000163B20
chronic hepatitis bEFO_0004239D019694B18.1
hepatitis b—D006509—
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent
Expires
Flag
FDA Information
Efavirenz / Emtricitabine / Tenofovir Disoproxil Fumarate, Atripla, Gilead Sciences
85981852029-04-28DP
90181922026-06-13U-750, U-1170
95454142026-06-13DPU-750, U-1170
85923972024-01-13DPU-750, U-1170
87162642024-01-13DPU-257
94570362024-01-13DPU-257
97441812024-01-13DPU-257
ATC Codes
J: Antiinfectives for systemic use
— J05: Antivirals for systemic use
— J05A: Direct acting antivirals
— J05AG: Non-nucleoside reverse transcriptase inhibitors
— J05AG03: Efavirenz
— J05AR: Antivirals for treatment of hiv infections, combinations
— J05AR06: Emtricitabine, tenofovir disoproxil and efavirenz
— J05AR11: Lamivudine, tenofovir disoproxil and efavirenz
HCPCS
No data
Clinical
Clinical Trials
495 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Hiv infectionsD015658EFO_0000764B20——1——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
HivD006678—O98.721———3
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameEfavirenz
INNefavirenz
Description
Efavirenz is 1,4-Dihydro-2H-3,1-benzoxazin-2-one substituted at the 4 position by cyclopropylethynyl and trifluoromethyl groups (S configuration) and at the 6 position by chlorine. A non-nucleoside reverse transcriptase inhibitor with activity against HIV, it is used with other antiretrovirals for combination therapy of HIV infection. It has a role as a HIV-1 reverse transcriptase inhibitor and an antiviral drug. It is a benzoxazine, an acetylenic compound, an organochlorine compound, an organofluorine compound and a member of cyclopropanes.
Classification
Small molecule
Drug classFc fusion protein; antivirals: non-nucleoside reverse transcriptase inhibitors; benzoxazinone derivatives
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
O=C1Nc2ccc(Cl)cc2[C@@](C#CC2CC2)(C(F)(F)F)O1
Identifiers
PDB—
CAS-ID154598-52-4
RxCUI—
ChEMBL IDCHEMBL223228
ChEBI ID119486
PubChem CID64139
DrugBankDB00625
UNII IDJE6H2O27P8 (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
CYP3A4
CYP3A4
Organism
Homo sapiens
Gene name
CYP3A4
Gene synonyms
CYP3A3
NCBI Gene ID
1576
Protein name
cytochrome P450 3A4
Protein synonyms
1,4-cineole 2-exo-monooxygenase, 1,8-cineole 2-exo-monooxygenase, Albendazole monooxygenase (sulfoxide-forming), Albendazole sulfoxidase, Cholesterol 25-hydroxylase, CYPIIIA3, CYPIIIA4, Cytochrome P450 3A3, Cytochrome P450 HLp, Cytochrome P450 NF-25, cytochrome P450, family 3, subfamily A, polypeptide 4, cytochrome P450, subfamily IIIA (niphedipine oxidase), polypeptide 3, cytochrome P450, subfamily IIIA (niphedipine oxidase), polypeptide 4, Cytochrome P450-PCN1, glucocorticoid-inducible P450, Nifedipine oxidase, P450-III, steroid inducible, Quinine 3-monooxygenase, taurochenodeoxycholate 6-alpha-hydroxylase
Uniprot ID
Q9UK50
Mouse ortholog
—
—
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Atripla – Gilead Sciences
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
Efavirenz
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Efavirenz
+
Emtricitabine
+
Tenofovir
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 22,973 documents
View more details
Safety
Black-box Warning
Black-box warning for: Atripla, Efavirenz, emtricitabine and tenofovir disoproxil fumarate, Efavirenz, lamivudine and tenofovir disoproxil fumarate, Symfi, Symfi lo
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
35,137 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use